Literature DB >> 8621376

Molecular determinants of high affinity dihydropyridine binding in L-type calcium channels.

B Z Peterson1, T N Tanada, W A Catterall.   

Abstract

The pore-forming alpha1 subunit of L-type voltage-gated Ca2+ channels is pharmacologically modulated by dihydropyridine (DHP) Ca2+ antagonists and agonists. Site-directed mutation of amino acids within transmembrane segments IIIS6 and IVS6 to those characteristic of DHP-insensitive channels revealed 2 mutations in IIIS6 (I1049F and I1052F) and 4 mutations in IVS6 (Y1365I, M1366F, I1372M, and I1373L) with increased KD values for (+)-[3H]PN200-110 binding. A tyrosine residue (Y1048) in IIIS6 that is conserved between DHP-sensitive and -insensitive Ca2+ channels was also altered by mutagenesis. Y1048F had a KD for (+)-[3H]PN200-110 binding that was increased 12-fold, and Y1048A had a KD at least 1000-fold higher than that of wild-type. These results support the hypothesis that transmembrane segments IIIS6 and IVS6 both contribute critical amino acid residues to the DHP receptor site and that Tyr-1048 within transmembrane segment IIIS6 is required for high affinity DHP binding, even though it is conserved between DHP-sensitive and -insensitive Ca2+ channels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621376     DOI: 10.1074/jbc.271.10.5293

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  PF-06526290 can both enhance and inhibit conduction through voltage-gated sodium channels.

Authors:  Lingxin Wang; Shannon G Zellmer; David M Printzenhoff; Neil A Castle
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

Review 2.  Molecular basis of drug interaction with L-type Ca2+ channels.

Authors:  J Mitterdorfer; M Grabner; R L Kraus; S Hering; H Prinz; H Glossmann; J Striessnig
Journal:  J Bioenerg Biomembr       Date:  1998-08       Impact factor: 2.945

3.  Predominance of the alpha1D subunit in L-type voltage-gated Ca2+ channels of hair cells in the chicken's cochlea.

Authors:  R Kollmar; L G Montgomery; J Fak; L J Henry; A J Hudspeth
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

4.  Dissection of functional domains of the voltage-dependent Ca2+ channel alpha2delta subunit.

Authors:  R Felix; C A Gurnett; M De Waard; K P Campbell
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

Review 5.  Structural Basis for Pharmacology of Voltage-Gated Sodium and Calcium Channels.

Authors:  William A Catterall; Teresa M Swanson
Journal:  Mol Pharmacol       Date:  2015-04-06       Impact factor: 4.436

6.  Comparative molecular modelling study of the calcium channel blockers nifedipine and black mamba toxin FS2.

Authors:  K J Schleifer
Journal:  J Comput Aided Mol Des       Date:  1997-09       Impact factor: 3.686

7.  Conformational changes induced in voltage-gated calcium channel Cav1.2 by BayK 8644 or FPL64176 modify the kinetics of secretion independently of Ca2+ influx.

Authors:  Merav Marom; Yamit Hagalili; Ariel Sebag; Lior Tzvier; Daphne Atlas
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

8.  1,4-Dihydropyridine derivatives with T-type calcium channel blocking activity attenuate inflammatory and neuropathic pain.

Authors:  Chris Bladen; Vinicius M Gadotti; Miyase G Gündüz; N Daniel Berger; Rahime Şimşek; Cihat Şafak; Gerald W Zamponi
Journal:  Pflugers Arch       Date:  2014-07-03       Impact factor: 3.657

9.  Molecular simulations study of novel 1,4-dihydropyridines derivatives with a high selectivity for Cav3.1 calcium channel.

Authors:  Xiaoguang Liu; Hui Yu; Xi Zhao; Xu-Ri Huang
Journal:  Protein Sci       Date:  2015-08-25       Impact factor: 6.725

10.  Addition of a single methyl group to a small molecule sodium channel inhibitor introduces a new mode of gating modulation.

Authors:  Lingxin Wang; Shannon G Zellmer; David M Printzenhoff; Neil A Castle
Journal:  Br J Pharmacol       Date:  2015-10-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.